

Jeffrey McKee MS PhD DABT DSP

Work

BioPhia Consulting
100 S. Saunders Road #111813 Suite 150
Lake Forest, IL 60045
Phone: (847)302-8152
E-mail: jmckee@biophia.com

SUMMARY

Over 25 years of research and development experience assessing the nonclinical efficacy and safety of pharmaceuticals, medical devices, and biologics. I possess a broad technical knowledge base and skill set spanning animal modeling, systems physiology, safety pharmacology, descriptive toxicology, regulatory toxicology, and toxicological risk assessment.

PROFESSIONAL EXPERIENCE

BIOPHIA CONSULTING

Oct 2021-Present

Principal Consultant

Providing clients with practical solutions and timely, cost-competitive advice in the areas of nonclinical safety and efficacy that make a positive difference in their projects and products. Essential duties and responsibilities included:

- Develop nonclinical plans to enable IND and marketing approval.
- Develop nonclinical plans for qualification of drug impurities and excipients.
- Perform toxicological risk assessment of extractables and leachables data in compliance with ISO 10993-1, ISO 10993-17, ISO/TS 21726, and/or PQRI for submissions to FDA and other regulatory agencies.
- Perform nitrosamine risk assessments.
- Perform risk assessments of particulate/foreign matter supporting manufacturing.
- Evaluate and summarize biocompatibility and general toxicology data ensuring compliance with the relevant regulatory requirements and standards.
- Advise clients on technical issues related to nonclinical testing.
- Evaluate and determine relevance of unexpected nonclinical results.

BAXTER HEALTHCARE CORPORATION

1997-Oct 2021

Principal Scientist

2018-Oct 2021

Served as an individual contributor, global nonclinical subject matter expert supporting new product development as well as existing products, and mentor/trainer to junior staff and new hires. Essential duties and responsibilities included:

- Develop and manage toxicology testing strategies to qualify impurities in pharmaceutical products according to global requirements

- Author and review toxicology risk assessments of medical device and pharmaceutical extractable and leachable profiles
- Author/review content (e.g., CTD) for global submissions
- Collaborate with regulatory to respond to requests/deficiencies from global regulatory agencies
- Perform nonclinical change control impact assessments and collaborate with cross functional team members to develop appropriate testing strategies
- Collaborate with medical and pharmacovigilance on product-related complaints and field corrective actions
- Support manufacturing on quality issues impacting product release and development of PDEs
- Collaborate with business development to perform external technology evaluations

Principal Scientist**2014-2018**

Primary responsibility for managing the US-based regulatory toxicology function. Secondary responsibilities included technical oversight for outsourced safety pharmacology and animal model development activities. Essential duties and responsibilities included:

- Provide technical and strategic leadership for department comprised of six scientists (3 PhD, 2 MS and 1 BS)
- Responsible for hiring, training, compensation, performance evaluation and development of team members
- Participate on project teams advising on testing and issue-resolution strategies
- Author, review and approve toxicological risk assessments for new product development and product change control activities
- Interact with regulatory agencies as needed
- Collaborate with medical and pharmacovigilance on product-related complaints
- Support manufacturing on quality issues impacting product release
- Collaborate with business development performing external technology evaluations
- Oversee safety pharmacology and animal modeling activities including study design, protocol review, data interpretation and report review
- Serve on Baxter's Global Animal Welfare committee
- In-depth knowledge and understanding of GLP, ICH and ISO10993.

Senior Research Scientist**2007-2014**

Primary responsibility for managing the Physiology department for conducting experimental and safety pharmacology studies, efficacy testing, and support of products in the field. Essential duties and responsibilities included:

- Provided technical leadership to department comprised of GLP-compliant laboratories and five scientists (1 PhD, 1 DVM, 2 MS and 1 BS)
- Responsible for hiring, training, compensation, performance evaluation and development of team members
- Designed and conducted GLP and non-GLP cardiovascular, respiratory, and renal pharmacodynamic studies

- Established new-to-Baxter animal models including: canine model of hemofiltration; sheep model of hemodialysis; myocardial infarction in swine and rats, mouse hindlimb ischemia; swine acute wound healing; mouse skin graft rejection; rat glomerulonephritis; renal ischemia-reperfusion injury in rats and mice; guinea pig airway irritation and mouse local lymph node assay
- Participated on project teams advising on testing and issue-resolution strategies
- Evaluated external technologies supporting corporate business development initiatives
- Provided firefighting support for products in the field
- Secured, validated and implemented large animal telemetry system for cardiovascular and respiratory monitoring
- Participated in the Baxter-Northwestern Alliance program to foster research collaborations with colleagues from surrounding universities for new product ideation
- Chaired Baxter's IACUC

Research Scientist**2003-2007**

Primary responsibility for managing the Physiology department for conducting experimental and safety pharmacology studies, efficacy testing, and support of products in the field. Essential duties and responsibilities included:

- Managed department comprised of GLP-compliant laboratories and two scientists (1 MS and 1 BS)
- Provide technical leadership and responsible for hiring, training, compensation, performance evaluation and development of team members
- Served as Study Director on GLP toxicology studies including subchronic studies in rodents and non-rodents including impurity qualification studies.
- Managed and monitored outsourced genetic toxicology testing
- Prepared nonclinical modules of Common Technical Documents for ondansetron and ciprofloxacin
- Established new-to-Baxter animal models including hypovolemic shock in swine; and sheep, swine and canine models to evaluate different hemo- and peritoneal dialysis modalities
- Served on cross-functional project teams
- Evaluated external technologies in support of corporate business development initiatives
- Provided firefighting support for products in the field including over-sulfated-chondroitin-sulfate contaminant in heparin
- Chaired Baxter's IACUC

Associate Research Scientist**1999-2003**

- Served as Study Director on GLP and non-GLP cardiovascular, respiratory and renal pharmacodynamic studies
- Ensured laboratory was in compliance with all internal and external requirements including SOP generation and maintenance; and equipment validation, calibration and maintenance
- Served on cross-functional project teams

Post-doctoral Research Fellow**1997-1999**

Studied the pharmacodynamics and pathophysiology of modified hemoglobins in swine

PROFESSIONAL ACTIVITIES

- Extractables and Leachables Safety Information Exchange Safety Working Group, 2017-2021
- Co-chair Safety Pharmacology Society continuing education courses: *Respiratory System Safety Pharmacology and Case Studies*, 2014
- Member AAMI BE/WG 03 – Animal protection aspects Working Group 2012-Present
- Chairman, Institutional Animal Care and Use Committee, Baxter Healthcare Corporation, Round Lake IL, 2002-2014
- Society of Toxicology Standard of Knowledge Committee 2012-2013
- Co-chair Safety Pharmacology Society continuing education courses: *Safety Pharmacology Endpoints: Integration into Toxicology Studies* and *Supplemental Safety Pharmacology Studies*, 2011
- Member of the Safety Pharmacology Society Continuing Education committee, 2010
- American Physiological Society Animal Care and Experimentation committee, 2010-2013
- American Physiological Society Cardiovascular Section Industry-Foundations Liaison committee, 2009-2011
- Participated in Safety Pharmacology Society inaugural webinar: *Understanding S7A-An Essential Guideline to Safety Pharmacology*, 2009
- Member of the Safety Pharmacology Society Continuing Education committee, 2009
- Co-chair Safety Pharmacology Society, continuing education course: *Safety Pharmacology: Introduction, Application and Interpretation*, 2009
- Member of the Safety Pharmacology Society Academic Outreach committee, 2008
- Member of the Safety Pharmacology Society Continuing Education committee, 2008
- Co-chair Safety Pharmacology Society continuing education course: *Introduction to Safety Pharmacology: Review and Application of the ICH S7A Guideline*, 2008

EDUCATION

- Ph.D., *Effects of Supplemental Ascorbic Acid on Energy Conversion and Performance of the Domestic Fowl Exposed to High Ambient Temperatures*, Physiology, Animal Sciences, University of Illinois, Urbana-Champaign IL, 1997
- M.S., Physiology, Animal Sciences, University of Illinois, Urbana-Champaign IL, 1995
- A.B., Biology, Augustana College, Rock Island IL, 1990

CERTIFICATIONS

- Diplomate, American Board of Toxicology, 2010-Present
- Diplomate, Safety Pharmacology Society, 2015-Present

MEMBERSHIPS

- Society of Toxicology, 2011-Present
- Safety Pharmacology Society, 2007-Present
- American Physiological Society, 1998-2018
- American Association of Laboratory Animal Science, 1998-2014

AWARDS

- *Saving the Overpouch*. Global Corporate Technical Award – Endeavor, 2015
- *Next Generation Brevibloc*. Divisional Award – Ingenuity, 2011
- *Demonstrated Efficacy of the Bax69 anti-MIF Antibody*. Divisional Award – Stellar, 2010
- *Qualification of Complex Degradation Profile of Cefepime Injection*. Divisional Award – Outstanding Innovation, 2009
- *Discriminating Animal Models*. Divisional Award – Stellar, 2009
- *Successful Investigation of Heparin Contamination*. Global Corporate Technical Award – Customer First, 2008
- *Cardiovascular Disease Model Development Supporting Regenerative Medicine*. Divisional Award – Ingenuity, 2007
- *Support of the Recombinant Hemoglobin Program*. Divisional Award – Outstanding Contribution, 2002
- *Development of Dual Lumen Catheter for Peritoneal Dialysis*. Global Corporate Technical Award – Outstanding Innovation, 2000

PRESENTATIONS

External

- *An Enantiomerically Pure Formulation of Esmolol Attenuates Hypotension and Preserves Heart Rate Control in Dogs*. Safety Pharmacology Society (poster), 2014
- *Interpreting Cardiovascular Signals in the Context of Risk Assessment*. Midwest Regional Chapter of the Society of Toxicology (oral), 2013
- *Understanding S7A-An Essential Guideline to Safety Pharmacology*. Safety Pharmacology Society inaugural webinar titled *Overview of ICH Guideline S7A* (oral), 2009
- *Safety Pharmacology: Setting the Stage*. Safety Pharmacology Society annual meeting (oral), 2008
- *Therapeutic Potential of Intramyocardial Transplanted CD34+ Cells in Myocardial Ischemia*. Experimental Biology annual meeting (poster), 2008
- *Solute Clearance During Continuous Flow PD (CFPD): One vs. Two Catheters*. Annual Dialysis Conference meeting (oral), 2001

Internal

- *Animal Models Supporting Therapies in Development and in the Field*. Medical Products R&D Seminar Series (oral), 2012
- *Animal Modeling: Not All Glitz and Glamour*. Toxicology Seminar Series (oral), 2011

- *Basic Cardiovascular Physiology and Mechanisms of Toxicity*. Toxicology Seminar Series (oral), 2010
- *Safety Pharmacology: A View from 30,000 Feet*. Toxicology Seminar Series (oral), 2009
- *A Swine Model of Wound Healing: Leveraging Expertise Across the Organization in Support of Corporate Business Development*. Achievement Awards (poster), 2009
- *Animals in Research and Development: Private and Public Interests*. AAALAS Certification Course (oral), 2009
- *Life Sciences and BioScience: Partners for Success*. 9th Biannual Process Development Technical Services Conference (oral), 2008
- *rFVIII Half-Life Crash Program Success*. Achievement Awards (poster), 2008
- *Analysis of Contaminated Heparin Associated with Adverse Events*. Achievement Awards (poster), 2008
- *Cardiovascular Disease Model Development Supporting Regenerative Medicine*. Achievement Awards (poster), 2007

PATENTS

- US 8,829,047 B2: Methods of Controlling Venous Irritation Associated with the Treatment of a Cardiac Disorder. September 9, 2014.
- US 8,686,036 B2: Methods of Controlling Heart Rate While Minimizing and/or Controlling Hypotension. April 1, 2014.

PUBLICATIONS

Book Chapters

Case Study: Contamination of Heparin with Oversulfated Chondroitin Sulfate. In *Heparin – A Century of Progress*. Handbook of Experimental Pharmacology, Vol. 207 ed. Rebecca Lever, Barbara Mulloy and Clive P. Page. 2012

Articles in Peer-reviewed Journals

- **McKee, J.**, F. Clemo, M. Hawk, C. Hassler, R. Moutvic, M. Hawk, G. Ritchie and P. Monroe. Subchronic Exposure to Sub-Mac Concentrations of Desflurane Does Not Impair Neurobehavior and Cognition in Rats. *Anesthesiology (in process)*.
- Werner Höllriegl, Alexander Bauer, Bernhard Baumgartner, Barbara Dietrich, Patrice Douillard, Randolph J. Kerschbaumer, Gerald Höbarth, **Jeffrey S. McKee**, Alexander Schinagl, Frederick W.K. Tam, Michael Thiele, Alfred Weber, Martin Wolfsegger, Marietta Turecek, Eva-Maria Muchitsch, Friedrich Scheiflinger, Helmut Glantschnig. Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis. *European Journal of Pharmacology* 820 (2018) 206-216.
- Sungsoo S. Lee, Erin L. Hsu, Marco Mendoza, Jason Ghodasra, Michael S. Nickoli, Amruta Ashtekar, Mahesh Polavarapu, Jacob Babu, Rehan M. Riaz, Joseph D. Nicholas, David Nelson, Sohaib Z. Hashmi, Stuart R. Kaltz, Jeffrey S. Earhart, Bradley R. Merk, **Jeff S. McKee**, Shawn F. Bairstow, Ramille N. Shah, Wellington K. Hsu, Samuel I. Stupp. Gel

Scaffolds of BMP-2-Binding Peptide Amphiphile Nanofibers for Spinal Arthrodesis. *Advanced Healthcare Materials* 4(1) (2015) 131-141.

- **McKee, J.**, B. Rabinow, J. Daller, B. Brooks, B. Baumgartner and P. Rohatgi. An enantiomerically pure formulation of esmolol attenuates hypotension and preserves heart rate control in dogs. *Anesthesiology* 121 (2014) 1184-1193.
- **McKee, J.**, J. Daller, B. Baumgartner and S. Pettinger. Evaluation of the sensitivity of a new fully implantable telemetry device and the importance of simultaneously measuring cardiac output and left ventricular pressure. *J Pharmacol Toxicol Methods* 69 (2014) 229-236.
- Lewis, K., **J. McKee**, A. Schiviz, A. Bauer, M. Wolfsegger and A. Goppelt. Randomized, Controlled Comparison of Advanced Hemostatic Pads in Hepatic Surgical Models. *ISRN Surgery Volume 2014*.
- **McKee, J.** and P.C. Harrison. Supplemental ascorbic acid does not affect inferred heat loss in broiler chickens exposed to elevated temperature. *J Therm Biol* 38 (2013) 159-162.
- **McKee, J.**, B. Brooks, J. Daller, J. Gass, D. Pantaleone, P. Zieske, P. Mussi and B. Moreaux. A comparison of the potential for acute cardiopulmonary adverse effects in dogs during continuous veno-venous hemofiltration with Accusol 35 Solution with and without induced calcium carbonate particles. *Blood Purif* 36 (2013) 84-91.
- Daller J., **J. McKee**, J. Wong, and B. Brooks. An inexpensive system for evaluating the tussive and anti-tussive properties of chemicals in conscious, unrestrained guinea pigs. *J Pharmacol Toxicol Methods* 66(3) (2012) 232-237.
- **McKee, J.** and B. Brooks. Sodium Nitrite Therapy Fails to Improve Tissue Perfusion in a Mouse Model of Hind Limb Ischemia: Slight Differences in Methodology May Be Responsible Casting Suspicion on the Reliability and Predictive Value of This Model. *J Pharmaceutical Negative Results* 2(2) (2011) 99-106.
- **McKee, J.** and J. Gass. Acetaminophen-Induced Forestomach Lesion in Normal Rats Following Intravenous Exposure. *Toxicol Pathol* 39(5) (2011) 861-866.
- **McKee, J.**, B. Rabinow, C. Cook and J. Gass. Nanosuspension Formulation of Itraconazole Eliminates the Negative Inotropic Effect of SPORANOX® in Dogs. *J Med Toxicol* 6 (2010) 331-336.
- **McKee, J.**, S. Bairstow, C. Szabo, J. Ray, T. Wielgos, P. Hu, E. Chess, M. Nordhaus, T. Hai, J. Campbell, S. Donovan, N. Viseux, N. Riedel, J. Cammack and R. Johnson. Structure Elucidation and Biological Activity of the Over-Sulfated Chondroitin Sulfate Contaminant in Baxter Heparin. *J Clin Pharmacol* 50 (2010) 1159-1170.
- Bairstow, S., **J. McKee**, M. Nordhaus and R. Johnson. Identification of a Simple, Sensitive Microplate Method for the Detection of Over-Sulfated Chondroitin Sulfate in Heparin Products. *Analytical Biochemistry* 338 (2009) 317-321.
- Koelkebeck, K.W., **J.S. McKee**, P.C. Harrison, and C.M. Parsons. Performance of Laying Hens Provided Water from Two Sources. *J Appl Poultry Res* 8 (1999):374-379.
- **McKee, J. S.**, P. C. Harrison, and G. L. Riskowski. Effects of supplemental ascorbic acid on the energy conversion of broiler chickens during heat exposure and feed withdrawal. *Poultry Sci* 76:1278-1286 (1997).

- **McKee, J. S.**, and P. C. Harrison. Effects of supplemental ascorbic acid on the performance of broiler chickens exposed to multiple concurrent stressors. *Poultry Sci* 74:1772-1785 (1995).
- Maghirang, R. G., G. L. Riskowski, P. C. Harrison, H. W. Gonyou, L. A. Sebek, and **J. S. McKee**. An individually ventilated caging system for laboratory rats. *ASHRAE Trans* 100(1):913-920 (1994).

Articles in Non-peer-reviewed Journals

- **McKee, J. S.** Stress and Nutrition Interactions: Emphasis on Vitamin C. *Proceedings from the 58th Minn. Nutrition Conference & BASF Technical Symposium*, Minn. Extension Service, University of Minnesota (1997).
- **McKee, J. S.** What does physiological stress mean to your flock? *Proceedings from the 13th Minn. Poultry Service Workshop*, Minn. Extension Service, University of Minnesota (1997).

Posters/Abstracts

- Baumgartner, B., A. Bauer, G. Leung, **J. McKee** and K. Lewis. Use of a PEG-coated collagen patch for sutureless repair of severe arterial bleeding in a porcine model of cardiovascular surgery. 16th *European Congress of Trauma & Emergency Surgery (2015)*.
- **McKee, J.**, B. Rabinow and J. Daller. An Enantiomerically Pure Formulation of Esmolol Attenuates Hypotension and Preserves Efficacy in Dogs. *Society of Safety Pharmacology (2014)*.
- Baumgartner, B., **J. McKee**, R. Kerschbaumer, F. Clemo, A. Hutchcraft, M. Wolfsegger, A. Weber, G. Hoebarth, F. Tam, F. Scheiflinger, H.P. Schwarz, E. Muchitsch and H. Werner. Efficacy of a Human Anti-Macrophage Migration Inhibitory Factor Antibody in a Rat Model of Proliferative Nephritis. *American Society of Nephrology (2012)*.
- Lewis, K.M., S.L. Smith and **J.S. McKee**. Surgical porcine myocardial infarction model through permanent left circumflex artery occlusion. 3rd *Tissue Engineering and Regenerative Medicine International Society World Congress (2012)*.
- Hsu, W.K., M. Mendoza, J. Babu, V. Llievski, M. Polavarapu, R.M. Riaz, G.C. Roc, D. Nelsom, K. Maharaj, S. Kaltz, J.D. Nicholas, S.L. Stupp, S.R. Rock, **J.S. McKee**, S.F. Bairstow, and E.L. Hsu. Evaluation of a Novel Bioactive Nanofiber Scaffold to Elicit Spine Fusion in a Rodent Arthrodesis Model. *Lumbar Spine Research Society (2012)*.
- Hsu, W.K., M. Mendoza, J. Babu, V. Llievski, M. Polavarapu, R.M. Riaz, G.C. Roc, D. Nelsom, K. Maharaj, S. Kaltz, J.D. Nicholas, S.L. Stupp, S.R. Rock, **J.S. McKee**, S.F. Bairstow, and E.L. Hsu. A Bioactive, Biodegradable, BMP-2-binding Nanofiber Scaffold to Enhance Spinal Arthrodesis in a Rat Model. *North American Spine Society (2012)*.
- Daller J., **J. McKee**, J. Wong, and B. Brooks. Desflurane-Induced Coughing in Conscious Guinea Pigs is Mediated through TRPA1. *Experimental Biology (2012)*.
- **McKee, J.**, B. Brooks, J. Daller, J. Gass, D. Pantaleone, P. Zieske, P. Mussi and B. Moreaux. Evaluation of the potential adverse effects associated with calcium carbonate precipitate during continuous veno-venous hemofiltration (CVVH). 32nd *International Symposium on Intensive Care and Emergency Medicine (2012)*.

- **McKee, J.**, B. Brooks, J. Daller, J. Gass, D. Pantaleone, P. Zieske, P. Mussi and B. Moreaux. Evaluation of the potential adverse effects associated with calcium carbonate precipitate during continuous veno-venous hemofiltration (CVVH). *CRRT (2012)*.
- Hsu, W.K., M. Mendoza, J. Babu, V. Llievski, M. Polavarapu, R.M. Riaz, G.C. Roc, D. Nelsom, K. Maharaj, S. Kaltz, J.D. Nicholas, S.L. Stupp, S.R. Rock, **J.S. McKee**, S.F. Bairstow, and E.L. Hsu. Evaluation of Spinal Fusion Capacity by a Biodegradable Nanogel. *American Academy of Orthopaedic Surgeons (2012)*.
- Muller, M., N. Tiwari, M. Desch, **J. McKee**, B. Brooks and A.A. Bernardo. In Vitro and In Vivo Characterization of a New Pumping System in a New Hemodialysis Device. *American Society of Nephrology (2011)*.
- **McKee, J.** and B. Brooks. Predictive Value of the Mouse Model of Critical Limb Ischemia: Methodological Differences May Dictate the Outcome of Preclinical Efficacy. *Experimental Biology (2011)*.
- Baumgartner, B., **J. McKee**, S. Young, and F. Clemo. Substrain Susceptibility in a Rat Model of Crescentic Glomerulonephritis. *STP/IFSTP 2010 Joint Symposium (2010)*.
- Brooks, B., **J. McKee**, B. Baumgartner, D. Rice, D. Amrani, and D. Motlagh. Dose-Response Relationship of Human CD34+ Cells in an Athymic Rat Model of Myocardial Infarction. *Experimental Biology (2010)*.
- Brooks, B. and **J. McKee**. Age-Dependent Impairment in Tissue Perfusion in the Fox n1^{nu/nu} Nude Mouse: Potential for Better Predicting the Efficacy of Cell-Based, Proangiogenic Therapies. *Experimental Biology (2009)*.
- D. Motlagh, H.L. Ting, A. Cohen, B. Tawil, I. Catelas, S. Smith, S. Donovan, A. Yardimci, **J. McKee**, B. Brooks, L. Stojanovic, J. Diorio, and D. Amrani. Fibrin Sealant Structure Impacts CD34+ Cell Function: Outcomes of Fibrin Scaffold Stem Cell in Preclinical Studies of Critical Limb Ischemia. *XX International Fibrinogen Workshop (2008)*.
- **J. McKee**, L. Palmer, D. Rice, L. Anderson, J. Gass, D. Motlagh, S. Pokropinski, D. Amrani, and J. Kemshead. Therapeutic Potential of Intramyocardial Transplanted CD34+ Cells in Myocardial Ischemia. *Experimental Biology (2008)*.
- Rashba-Step, J., Sullivan A., Mehr E., Cutler D., Mason K., Cook C., Hogeland K, and **McKee J.** Pulmonary Delivery of Human Growth Hormone using PROMAXX Technology. *American Association of Pharmaceutical Scientists Journal Vol. 8, No. S1 (2006)*.
- **McKee, J. S.**, Marchand G. R., DeLeo M., and Ruddell S. Solute Clearance During Continuous Flow Peritoneal Dialysis (CFPD) Using the GENESIS Dual Lumen Catheter. *9th Science and Technology Symposium 9: (2001)*.
- **McKee, J.**, Marchand G., and Doyle M. Recombinant Human Hemoglobin rHb2.0 for Injection on Pig Cardiovascular Function. *9th Science and Technology Symposium 9: (2001)*.
- Langdon, **J., McKee, J.**, and Farrell L. Investigation of Leukoreduction Filter Failure with Sickle Trait Positive Blood. *9th Science and Technology Symposium 9: (2001)*.
- Bundle, A., Martucci, J., Bui, T., Mullan, J., Marchand, G. and **McKee, J.** Closed Loop Infusion Control. *9th Science and Technology Symposium 9: (2001)*.
- **McKee, J. S.**, Marchand G. R., and DeLeo M. Solute Clearance During Continuous Flow PD (CFPD). *Peritoneal Dialysis International 21(Suppl. 1): (2001)*.

- **McKee, J. S.**, Marchand G. R., DeLeo M., and Ruddell S. Solute Clearance During Continuous Flow PD (CFPD) Using A Dual-Lumen Catheter. *Peritoneal Dialysis International* 21(Suppl. 1): (2001).
- **McKee, J. S.**, Marchand G. R., DeLeo M., and Ruddell S. Solute Clearance During Continuous Flow PD (CFPD): One vs. Two Catheters. *Peritoneal Dialysis International* 21(Suppl. 1): (2001).
- Vonesh, E., **McKee J.**, Marchand G., and DeLeo M. Kinetic Modeling of Continuous Flow PD (CFPD). *Peritoneal Dialysis International* 21(Suppl. 1): (2001).
- Kunzler, J., J. Gass, G. Marchand, **J. McKee**, R. Meyers, and T. Lisi. The effect of DCLHb (Diaspirin Cross-Linked Hemoglobin) on the clearance of creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and alanine aminotransferase (ALT). *8th Science and Technology Symposium* 8:41 (1999).
- **McKee, J. S.**, K. W. Koelkebeck, and P. C. Harrison. Effect of Aviguard® administration on the performance of broiler chicks subjected to heat stress and coccidiosis. *Poultry Sci.* 77(Suppl. 1): (1998).
- Koelkebeck, K. W., **J. S. McKee**, P. C. Harrison, and C. M. Parsons. Performance of laying hens provided well drinking water. *Poultry Sci.* 77(Suppl. 1): (1998).
- **McKee, J. S.**, and P. C. Harrison. Relative bioavailability of a stabilized ascorbic acid blend in the drinking water of broiler chickens. *Poultry Sci.* 76(Suppl. 1):130 (1997).
- **McKee, J. S.**, and P. C. Harrison. Supplemental ascorbic acid may facilitate evaporative heat loss in heat-stressed broiler chickens. *FASEB* 11(3):A87 (1997).
- Harrison, P. C., G. L. Riskowski, J. E. Novakofski, and **J. S. McKee**. Effects of a semipurified diet on carcass, fecal, and urine characteristics of rats. *FASEB* 10(3):A215 (1996).
- **McKee, J. S.**, and P. C. Harrison. Ascorbic acid-induced reductions in the respiratory quotient of heat-stressed chickens may result from increased availability of fatty acids for energy purposes. *Poultry Sci.* 75(Suppl. 1):1 (1996).
- **McKee, J. S.**, and P. C. Harrison. Does supplemental ascorbic acid affect nutrient partitioning in broiler chickens during heat stress? *Poultry Sci.* 74 (Suppl. 1):82 (1995).
- **McKee, J. S.**, P. C. Harrison, G. L. Riskowski, and J. Johnson. Effects of diet on gastrointestinal and whole body growth of laboratory rats. *FASEB* 9(3):A3203 (1995).
- **McKee, J. S.**, and P. C. Harrison. Effect of supplemental ascorbic acid on the performance of broiler chickens exposed to multiple concurrent stressors. *Poultry Sci.* 73 (Suppl. 1):59 (1994).
- Maghirang, R.G., G.L. Riskowski, P.C. Harrison, H.W. Gonyou, L. Sebek, and **J. McKee**. 1994. An individually ventilated caging system for laboratory rats. *ASHRAE Transactions* 100(1):913-920.
- **McKee, J. S.**, P. C. Harrison, H. W. Gonyou, G. L. Riskowski, L. A. Sebek, and R. G. Maghirang. Effect of double density housing of laboratory rats in simulated space shuttle transport caging. *FASEB* 7(4):A620 (1993).

REFERENCES

Available upon request.